Pharvaris NV Ordinary Shares PHVS
News
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
Pharvaris Presents Data at the Bradykinin Symposium 2024
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
Pharvaris Says FDA Lifted Clinical Hold on Application for Deucrictibant
Pharvaris shares surge as treatment for severe swelling meets clinical trial goal